Former Chief Financial Officer · Travere Therapeutics, Inc. (TVTX)

Laura Clague

A named executive officer of Travere Therapeutics in every fiscal year CompBrief holds from FY2016 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,963,343

Salary $422,476Stock awards $761,200

FY2021: $1,934,671

7th of 7 named executive officers at Travere Therapeutics by FY2022 total.

7 named officers on file for Travere Therapeutics, FY2022

Laura Clague’s pay file — $29

  • 7 fiscal years of pay, line by line
  • 16 equity grants, each cited to its filing
  • TVTX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Travere Therapeutics’s whole pay program stands against its peers

  • Travere Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 13, 2023 (DEF 14A).

Free

Get Laura Clague’s full pay file as a PDF — free

More than this page: up to 10 years of Laura’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Laura Clague compensation by year

Travere Therapeutics Summary Compensation Table · all 7 fiscal years held
In US dollars, as Travere Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022
Salary$368,000$382,467$399,583$419,271$436,801$452,072$422,476
Bonus$0$0$0$0$0$0$0
Stock awards$243,450$304,913$497,803$215,520$432,880$403,200$761,200
Option awards$587,892$671,220$769,522$453,000$508,217$791,194$538,929
Non-equity incentive$157,165$129,938$185,150$200,747$254,239$271,625$222,600
Pension and deferred compensation$0$0$0$0$0$0$0
All other$7,950$8,100$8,250$15,044$16,577$16,580$18,138
Total$1,364,457$1,496,638$1,860,308$1,303,582$1,648,714$1,934,671$1,963,343

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 13, 2023, accession 0001438533-23-000016, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001438533-23-000016. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2023.

$1.4M
$1.5M
$1.9M
$1.3M
$1.6M
$1.9M
$2.0M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option4,167—$17.96
Option29,948—$26.88
Option14,896—$15.46

Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Travere Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Eric DubePresident, Chief Executive Officer and Director$5,753,490
Jula InrigChief Medical Officer$2,866,793
Christopher ClineChief Financial Officer$2,325,646
William RoteSenior Vice President and Head of Research and Development$2,033,381
Peter HeermaChief Commercial Officer$2,005,747
Elizabeth ReedSenior Vice President and General Council$1,998,516
Laura Clague · this pageFormer Chief Financial Officer$1,963,343

The full Travere Therapeutics compensation record

free company brief

This page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Laura Clague's compensation dossier · One-time report. No refunds.